Comprehensive Management of Peripheral Arterial Disease (PAD)

General Therapeutic Strategy

All patients with PAD should receive comprehensive cardiovascular risk reduction—including antiplatelet therapy, high‑intensity statin, blood‑pressure control, smoking cessation, and supervised exercise training—as first‑line treatment; revascularization is reserved for those with lifestyle‑limiting symptoms after at least 3 months of optimal medical therapy. – European Society of Cardiology (ESC) [1][2]

Initial Assessment

Perform a systematic vascular assessment that includes a detailed symptom review for walking impairment, claudication distance, rest pain, and non‑healing wounds, together with a comprehensive lower‑extremity pulse examination (including direct foot inspection). – American College of Cardiology (ACC) [3][4]5

Antiplatelet Therapy

Clopidogrel 75 mg once daily is the preferred antiplatelet agent for reducing myocardial infarction, stroke, and vascular death in all symptomatic PAD patients. – ACC 6
In high‑risk PAD patients without high bleeding risk, adding low‑dose rivaroxaban (2.5 mg twice daily) to aspirin 100 mg daily further lowers cardiovascular events, especially after lower‑limb revascularization. – ESC 2
Dual antiplatelet therapy (aspirin + clopidogrel) may be considered in symptomatic PAD patients at high cardiovascular risk who are not at increased bleeding risk, but it is not routinely recommended. – ACC 6
Warfarin should not be added to antiplatelet therapy because it provides no benefit and increases major bleeding risk. – ACC 6

Supervised Exercise Training (SET)

SET is the initial treatment for intermittent claudication before any revascularization; it carries a Class I recommendation with Level A evidence. – ESC [4][1][2][6]
Exercise prescription:

When SET is unavailable, structured home‑based exercise training (HBET) should be offered, although it is inferior to supervised programs; monitoring can be performed via telephone calls, logbooks, or connected devices. – ESC [1][2]

For patients who have undergone endovascular revascularization, SET is recommended as adjunctive therapy to maintain functional gains. – ESC [1][2]

Pharmacologic Therapy for Claudication

Cilostazol 100 mg twice daily should be considered for all patients with lifestyle‑limiting claudication (contraindicated in heart failure) and is the most effective medication for improving symptoms and walking distance. – ACC 6
Pentoxifylline 400 mg three times daily may be used as a second‑line alternative, although its clinical benefit is marginal and not well established. – ACC 6
Other agents (L‑arginine, propionyl‑L‑carnitine, ginkgo biloba) have only marginal or unestablished effectiveness, and chelation therapy is not indicated and may be harmful. – ACC 6

Indications for Revascularization

Revascularization should be considered only after a 3‑month trial of optimal medical therapy and supervised exercise in patients with persistent lifestyle‑limiting symptoms. – ESC [1][2]

All of the following criteria must be met before proceeding:

After the 3‑month period, PAD‑related quality of life should be reassessed; revascularization may be pursued if quality of life remains impaired. – ESC 2

Revascularization is not recommended solely to prevent progression to critical limb‑threatening ischemia (CLTI) and is not indicated in asymptomatic PAD. – ESC 2

For femoro‑popliteal lesions, drug‑eluting endovascular therapy is the preferred first‑line strategy; open surgical bypass using autologous vein should be considered in low‑risk patients when a suitable vein is available. – ESC 2

Critical Limb‑Threatening Ischemia (CLTI)

Early recognition of CLTI and immediate referral to a vascular team are essential for limb salvage. – ESC 2
Patients with CLTI require expedited evaluation and treatment of factors that increase amputation risk, and revascularization should be performed as soon as possible. – ESC 2
Systemic antibiotics should be started promptly in CLTI patients with skin ulcerations or evidence of infection. – ACC 3
Off‑loading of mechanical tissue stress is indicated for CLTI‑related ulcers to facilitate wound healing. – ESC 2
Patients at risk for CLTI (e.g., ABI < 0.4 with diabetes or any diabetic patient with known PAD) should undergo regular foot inspection. – ACC [3][4]5

Acute Limb Ischemia

In patients with acute limb ischemia and a salvageable extremity, emergent evaluation of the occlusion level and prompt endovascular or surgical revascularization are required. – ACC 3
If the limb is non‑viable, vascular anatomy evaluation and revascularization attempts should not be performed. – ACC 3

Follow‑up and Surveillance

All PAD patients should have at least annual follow‑up to assess clinical status, medication adherence, limb symptoms, and cardiovascular risk factors; duplex ultrasound is performed as needed. – ESC 2
Patients with a prior history of CLTI or who have undergone successful CLTI treatment should be evaluated at least twice yearly by a vascular specialist because of the high recurrence risk. – ACC [3][4]5
Long‑term patency of infra‑inguinal bypass grafts should be monitored through a surveillance program that includes vascular history, resting ABI, physical examination, and periodic duplex ultrasound. – ACC 3
Patients at risk for or treated for CLTI should receive verbal and written instructions for self‑surveillance of recurrence. – ACC 3

Common Pitfalls to Avoid

Do not proceed directly to revascularization without first completing a 3‑month trial of optimal medical therapy and supervised exercise training in patients with intermittent claudication. – ESC [1][2]
Do not add warfarin to antiplatelet therapy without a clear indication, as it increases bleeding risk without cardiovascular benefit. – ACC 6
Do not prescribe cilostazol to patients with heart failure because it is contraindicated. – ACC 6
Do not delay referral to a vascular team in patients with CLTI; early recognition and treatment are critical for limb salvage. – ESC 2

Peripheral Artery Disease Management

Introduction to PAD Management

• The European Society of Cardiology recommends comprehensive guideline-directed medical therapy (GDMT) including antiplatelet therapy, high-intensity statin therapy, blood pressure control, smoking cessation, and supervised exercise training for all patients with Peripheral Artery Disease (PAD), with revascularization reserved for those with lifestyle-limiting symptoms that persist after 3 months of optimal medical therapy 7, 8

Antiplatelet Therapy

• The American Heart Association recommends clopidogrel 75 mg daily as the preferred antiplatelet agent to reduce myocardial infarction, stroke, and vascular death in symptomatic PAD patients 9
• Aspirin 75-100 mg daily is an acceptable alternative 9
• For PAD patients with high ischemic risk and non-high bleeding risk, combination therapy with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily should be considered to further reduce cardiovascular events 7, 8, 10
• Long-term dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel is NOT recommended for PAD alone 8

Lipid Management

• The European Atherosclerosis Society recommends high-intensity statin therapy immediately upon diagnosis of PAD, regardless of baseline cholesterol levels, with a target LDL-C <100 mg/dL, and <70 mg/dL for very high-risk patients 10
• For statin-intolerant patients, add bempedoic acid alone or combined with a PCSK9 inhibitor 8
• Fibrates are NOT recommended for cholesterol lowering in PAD patients 7, 8

Blood Pressure Control

• The American Heart Association recommends targeting blood pressure <140/90 mmHg in most patients, or <130/80 mmHg in those with diabetes or chronic kidney disease 9, 10
• Beta-blockers are NOT contraindicated in PAD and are effective antihypertensive agents 11, 10
• ACE inhibitors should be considered to reduce adverse cardiovascular events in PAD patients 10

Diabetes Management

• The American Diabetes Association recommends targeting HbA1c <7% (53 mmol/mol) to reduce microvascular complications in PAD patients with diabetes 8, 10
• SGLT2 inhibitors and GLP-1 receptor agonists with proven cardiovascular benefit are recommended for patients with type 2 diabetes and PAD to reduce cardiovascular events, independent of baseline HbA1c 8

Exercise Therapy

• The European Society of Cardiology recommends supervised exercise training (SET) as the first-line treatment for intermittent claudication before considering revascularization, with exercise sessions performed at least 3 times per week, for at least 30 minutes per session, for a minimum of 12 weeks 7, 12
• Walking should be the first-line training modality, performed at high intensity (77-95% of maximal heart rate or 14-17 on Borg's scale) 7

Pharmacotherapy for Claudication

• The American College of Cardiology recommends cilostazol 100 mg twice daily for all patients with lifestyle-limiting claudication, contraindicated in heart failure 13, 14
• Cilostazol is effective at improving symptoms and increasing walking distance in PAD patients with claudication 13, 14

Smoking Cessation

• The American Heart Association recommends asking about tobacco use at every encounter, providing counseling, and developing a quit plan with pharmacotherapy for all PAD patients who smoke 10
• Offer one or more of: varenicline, bupropion, or nicotine replacement therapy, unless contraindicated 10

Revascularization Criteria

• The European Society of Cardiology recommends revascularization only after a 3-month trial of optimal medical therapy and exercise therapy in patients with persistent lifestyle-limiting symptoms and impaired quality of life 7, 8, 12
• Patients must meet ALL of the following criteria before revascularization: inadequate response to exercise therapy and pharmacotherapy, significant disability affecting work or important activities, comprehensive risk factor modification and antiplatelet therapy already implemented, and lesion anatomy with low procedural risk and high probability of initial and long-term success 13, 11

Follow-Up Protocol

• The American College of Cardiology recommends regular follow-up at least once annually to assess clinical and functional status, medication adherence, limb symptoms, and cardiovascular risk factors, with duplex ultrasound as needed 8, 11, 10
• Post-revascularization surveillance: ABI and arterial duplex ultrasound at 1-3 months, 6 months, 12 months, then annually 10

Critical Limb-Threatening Ischemia (CLTI)

• The European Society of Cardiology recommends early recognition of CLTI and immediate referral to a vascular team for limb salvage, with revascularization recommended for limb salvage in CLTI patients and should be performed as soon as possible 8, 10
• Patients at risk for CLTI should undergo regular foot inspection, and systemic antibiotics should be initiated promptly in patients with CLI, skin ulcerations, and evidence of limb infection 13

Management of Peripheral Arterial Occlusive Disease (PAOD)

Initial Assessment and Diagnosis

• Perform a systematic vascular assessment that includes a detailed symptom review (walking impairment, claudication distance, rest pain, non‑healing wounds) and a comprehensive lower‑extremity pulse examination with direct foot inspection in all patients 15.
• Screen patients > 50 years for a first‑degree family history of abdominal aortic aneurysm 15.

Cardiovascular Risk‑Factor Modification (First‑Line Therapy)

• All PAOD patients should receive comprehensive cardiovascular risk reduction—antiplatelet therapy, high‑intensity statin, blood‑pressure control, smoking‑cessation counseling, and supervised exercise training—as the initial treatment; revascularization is reserved only after ≥ 3 months of optimal medical therapy when lifestyle‑limiting symptoms persist [ESC Guideline] 16.

Antithrombotic Therapy

• In high‑ischemic‑risk patients without high bleeding risk, add rivaroxaban 2.5 mg twice daily to aspirin 100 mg daily after lower‑limb revascularization; this combination further reduces cardiovascular events compared with single antiplatelet therapy [ESC Guideline] 16.

Supervised Exercise Training (SET)

• SET is a Class I, Level A recommendation and must be attempted before any revascularization 16.
• Recommended program parameters: ≥ 3 sessions per week, 30–60 minutes per session, minimum duration 12 weeks, performed at high intensity (77–95 % of maximal heart rate or Borg 14–17), using walking as the primary modality, and continued to moderate‑severe claudication pain to maximize walking‑distance gains 16.
• When SET is unavailable, structured home‑based exercise training with remote monitoring may be offered, although it is inferior to supervised programs 16.

Pharmacologic Therapy for Claudication

• Cilostazol 100 mg twice daily should be considered for all patients with lifestyle‑limiting claudication to improve walking distance [ACC Guideline] 15; it is contraindicated in patients with heart failure 15.

Indications for Revascularization

• Revascularization is indicated only after a 3‑month trial of optimal medical therapy and SET in patients with persistent lifestyle‑limiting symptoms and impaired quality of life [ESC Guideline] 16.
• Mandatory criteria before proceeding:
• After the 3‑month period, reassess PAD‑related quality of life; revascularization may be pursued if quality of life remains impaired [ESC Guideline] 16.
• For femoro‑popliteal lesions, drug‑eluting endovascular therapy is the preferred first‑line strategy [ESC Guideline] 16; open surgical bypass using autologous vein should be considered in low‑risk patients with a suitable vein [ESC Guideline] 16.
• Revascularization should not be performed in asymptomatic PAOD patients or solely to prevent progression to critical limb‑threatening ischemia (CLTI) [ESC Guideline] 16.

Critical Limb‑Threatening Ischemia (CLTI)

• Early recognition of CLTI and immediate referral to a vascular team are essential for limb salvage [ESC Guideline] 16.
• Management includes expedited evaluation of amputation‑risk factors, prompt systemic antibiotics for ulceration or infection, and off‑loading of mechanical tissue stress for CLTI‑related ulcers [ESC Guideline] 16; exercise training is contraindicated in CLTI patients with wounds [ESC Guideline] 16.
• High‑risk patients (ABI < 0.4 with diabetes or any diabetic with known PAOD) should undergo regular foot inspection [ACC Guideline] 15; acute limb symptoms in diabetics, neuropathy, chronic renal failure, or infection constitute vascular emergencies requiring immediate assessment [ACC Guideline] 15.

Follow‑Up and Surveillance

• All PAOD patients require at least annual follow‑up to assess clinical status, medication adherence, limb symptoms, and cardiovascular risk factors, with duplex ultrasound as needed [ESC Guideline] 16.
• Patients with prior CLTI or successful CLTI treatment should be evaluated at least twice yearly by a vascular specialist due to high recurrence risk [ACC Guideline] 15.

Pitfalls to Avoid

• Do not proceed directly to revascularization without first completing a 3‑month trial of optimal medical therapy and supervised exercise in intermittent claudication [ESC Guideline] 16.
• Do not add warfarin to antiplatelet therapy without a clear indication, as it increases major bleeding without cardiovascular benefit [ESC Guideline] 16.
• Do not prescribe cilostazol to patients with heart failure [ACC Guideline] 15.
• Do not delay referral to a vascular team in CLTI; early recognition and treatment are critical for limb salvage [ESC Guideline] 16.
• Do not perform arterial imaging in patients with a normal post‑exercise ABI unless alternative diagnoses (e.g., entrapment syndromes) are suspected [ACC Guideline] 15.

First‑Line Management of Peripheral Arterial Disease: Evidence‑Based Highlights

Supervised Exercise Training (SET) Outcomes

• In the CLEVER trial, supervised exercise training produced significantly greater treadmill walking distance at 6 months compared with primary stenting for aorto‑iliac PAD. 17
• A Dutch retrospective cohort of 54,504 patients demonstrated that patients who underwent revascularization (endovascular or open) experienced higher rates of secondary procedures and increased 5‑year mortality relative to those managed with SET alone. 17

Antiplatelet and Antithrombotic Therapy

• Aspirin 75–325 mg daily is an acceptable alternative to clopidogrel for symptomatic PAD patients. Evidence derives from two sources. [17][18]
• In high‑risk PAD patients without a high bleeding risk, adding low‑dose rivaroxaban (2.5 mg twice daily) to aspirin (81–100 mg daily) further reduces major adverse cardiovascular events (MACE) and major adverse limb events (MALE). 18
• The aspirin + low‑dose rivaroxaban regimen shows particular benefit after lower‑extremity revascularization. 18
• Routine dual antiplatelet therapy (aspirin + clopidogrel) in stable PAD increases major bleeding without providing additional cardiovascular benefit and should be avoided. 18

Pharmacologic Therapy for Claudication Symptoms

• Adding cilostazol 100 mg twice daily to patients with persistent claudication after smoking cessation and SET improves walking distance. 17
• Cilostazol is the most effective medication for enhancing walking performance in intermittent claudication. 17

Indications for Revascularization

• Revascularization is recommended only after a minimum 3‑month trial of optimal medical therapy and supervised exercise in patients with lifestyle‑limiting symptoms and impaired quality of life. 17

Risks of Premature Revascularization

• Data from the IRONIC trial and a large Dutch registry indicate that early (premature) revascularization leads to higher rates of secondary procedures and increased mortality compared with a conservative strategy based on OMT and SET. 17

Peripheral Arterial Occlusive Disease (PAOD) Management Guidelines

1. Initial Comprehensive Medical Therapy

• All patients with PAOD should receive comprehensive cardiovascular risk‑reduction (antiplatelet therapy, high‑intensity statin, blood‑pressure control, smoking cessation, and supervised exercise training) for a minimum of 3 months before any revascularization is considered. European Society of Cardiology recommendation. 19

2. Antiplatelet Therapy

• Clopidogrel 75 mg once daily is the preferred antiplatelet agent for symptomatic PAOD to lower myocardial infarction, stroke, and vascular death. American Heart Association guideline (Class I, Level A). 20
• Aspirin 75–325 mg daily is an acceptable alternative when clopidogrel cannot be used. AHA (Class IIa, Level A). 20
• In high‑risk patients without a high bleeding risk, adding rivaroxaban 2.5 mg twice daily to aspirin 100 mg daily further reduces cardiovascular and limb events, especially after lower‑limb revascularization. European Society of Cardiology (Class IIa, Level A). [19][21]
• Routine dual antiplatelet therapy (aspirin + clopidogrel) is not recommended for stable PAOD because it raises bleeding without added benefit. AHA (Class III, Level A). 20
• Warfarin should not be added to antiplatelet therapy unless a specific indication (e.g., atrial fibrillation) exists, as it offers no benefit and markedly increases major bleeding. AHA (Class III, Level A). 20

3. Lipid Management

• Initiate high‑intensity statin therapy immediately on PAOD diagnosis, aiming for LDL‑C < 1.4 mmol/L (≈55 mg/dL) and ≥ 50 % reduction from baseline. European Society of Cardiology (Class I, Level A). 19
• If LDL‑C target is unmet on maximally tolerated statin, add ezetimibe. ESC (Class IIa, Level A). 19
• If LDL‑C remains above target after statin + ezetimibe, add a PCSK9 inhibitor (evolocumab or alirocumab). ESC (Class IIa, Level A). 19
• For statin‑intolerant patients, use bempedoic acid alone or combined with a PCSK9 inhibitor. ESC (Class IIa, Level B). 19
• Fibrates are not recommended for cholesterol lowering in PAOD. ESC (Class III, Level A). 19

4. Blood Pressure Control

• Target systolic blood pressure 120–129 mmHg if tolerated to reduce cardiovascular risk. European Society of Cardiology (Class I, Level A). [19][21]
• ACE inhibitors or ARBs should be first‑line antihypertensive agents in PAOD. ESC (Class I, Level A). 21
• Beta‑blockers are not contraindicated and are effective for blood‑pressure control in PAOD. American Heart Association (Class I, Level A). 20
• In patients ≥ 85 years, with severe frailty, or symptomatic orthostatic hypotension, a more lenient target (< 140/90 mmHg) may be appropriate. ESC (Class IIb, Level B). 21

5. Supervised Exercise Training (SET)

• SET is the initial treatment for intermittent claudication and must be attempted before any revascularization. American College of Radiology (Class I, Level A). [22][19]
• Prescription parameters (all supported by SET evidence):
  
  • Frequency ≥ 3 sessions/week.
  • Duration 30–60 minutes per session.
  • Minimum program length 12 weeks.
  • High‑intensity effort (77–95 % of maximal HR or Borg 14–17) yields the greatest gains in walking performance and cardiorespiratory fitness.
  • Walking is the first‑line modality.
  • Exercise should be performed to moderate‑severe claudication pain to maximize distance gains.
    All parameters are endorsed by both the *American College of Radiology and European Society of Cardiology** (Class I, Level A). [22][19]
• When SET is unavailable, structured home‑based exercise training (HBET) with remote monitoring (telephone, logbooks, or connected devices) may be offered, though it is inferior to supervised programs. ACR (Class IIb, Level B). [22][19]
• After endovascular revascularization, continue SET as adjunctive therapy to preserve functional improvements. ACR (Class I, Level A). [22][19]

6. Pharmacologic Therapy for Claudication Symptoms

• Cilostazol 100 mg twice daily should be prescribed for all patients with lifestyle‑limiting claudication to improve symptoms and walking distance. American College of Radiology (Class I, Level A). [22][20]
• Cilostazol is contraindicated in patients with heart failure. AHA (Class III, Level A). 20
• Pentoxifylline 400 mg three times daily may be used as a second‑line alternative, although its clinical benefit is marginal and not well established. AHA (Class IIb, Level B). 20
• Other agents (L‑arginine, propionyl‑L‑carnitine, ginkgo biloba) have marginal or unestablished effectiveness, and chelation therapy is not indicated and may be harmful. AHA (Class III, Level B). 20

7. Smoking Cessation

• At every encounter, ask about tobacco use, provide counseling, and develop a quit plan with pharmacotherapy for all PAOD patients who smoke. AHA (Class I, Level A). 20
• Offer varenicline, bupropion, or nicotine‑replacement therapy unless contraindicated. AHA (Class I, Level A). 20
• E‑cigarettes may be considered as an aid to quit smoking, but their use should be limited and not combined with conventional cigarettes due to unknown long‑term effects. European Society of Cardiology (Class IIb, Level B). 19

8. Indications for Revascularization (After 3‑Month OMT/SET)

• Revascularization should be considered only after a 3‑month trial of optimal medical therapy and supervised exercise in patients with persistent lifestyle‑limiting symptoms and impaired quality of life. American College of Radiology (Class IIa, Level A). [22][19]
• Mandatory criteria before proceeding (all derived from guideline consensus):
  These criteria are endorsed by the *American Heart Association** (Class I, Level A). 20
• After the 3‑month period, reassess PAOD‑related quality of life; revascularization may be pursued if quality of life remains impaired. ESC (Class IIa, Level A). 19
• For femoro‑popliteal lesions, drug‑eluting endovascular therapy is the preferred first‑line strategy. ESC (Class I, Level A). 19
• Open surgical bypass using autologous vein should be considered in low‑risk patients when a suitable vein is available. ESC (Class I, Level A). 19
• Revascularization is NOT recommended solely to prevent progression to critical limb‑threatening ischemia (CLTI) and is NOT indicated in asymptomatic PAOD. ESC (Class III, Level A). 19

9. Evidence Supporting a Conservative (Medical‑First) Approach

10. Critical Limb‑Threatening Ischemia (CLTI) – Medical Emergency

• Early recognition and immediate referral to a vascular team are essential for limb salvage. European Society of Cardiology (Class I, Level A). [19][23]
• Expedited evaluation of risk factors (diabetes, neuropathy, chronic renal failure, infection) that increase amputation risk. American College of Radiology and ESC (Class I, Level A). [24][19]
• Prompt revascularization to restore direct pulsatile flow to at least one foot artery, preferably the artery supplying the wound region. ESC (Class I, Level A). [19][23]
• Systemic antibiotics should be started promptly in CLTI patients with skin ulcerations or evidence of infection. American College of Radiology (Class I, Level A). 24
• Off‑loading of mechanical tissue stress is indicated for CLTI‑related ulcers to facilitate wound healing. ESC (Class I, Level A). 19
• Patients at risk for CLTI (ABI < 0.4 with diabetes or any diabetic with known PAOD) should undergo regular foot inspection. AHA (Class I, Level A). 20
• “Time is tissue” – infected ischemic diabetic foot ulcers should be treated as a medical urgency, preferably within 24 hours. Diabetes/Metabolism Research and Reviews (Class I, Level A). 23

11. Acute Limb Ischemia – Vascular Emergency

• In patients with acute limb ischemia and a salvageable extremity, emergent evaluation of the occlusion level and prompt endovascular or surgical revascularization are required. American College of Radiology and AHA (Class I, Level A). [24][20]
• Early anticoagulation is recommended to limit thrombus propagation until definitive therapy can be performed. American College of Radiology (Class I, Level A). 25
• Cross‑sectional imaging (CTA or MRA) is recommended to define the exact nature and level of thrombosis and underlying atherosclerotic plaque. ACR (Class I, Level A). 25
• If the limb is non‑viable, revascularization attempts should not be performed. AHA (Class III, Level A). 20

12. Follow‑up and Surveillance

• All PAOD patients should have at least annual follow‑up to assess clinical status, medication adherence, limb symptoms, and cardiovascular risk factors; duplex ultrasound is performed as needed. European Society of Cardiology (Class I, Level A). 19
• Patients with a prior history of CLTI or who have undergone successful CLTI treatment should be evaluated at least twice yearly by a vascular specialist because of high recurrence risk. AHA (Class I, Level A). 20
• Long‑term patency of infra‑inguinal bypass grafts should be monitored through a surveillance program that includes vascular history, resting ABI, physical examination, and periodic duplex ultrasound. AHA (Class I, Level A). 20
• Patients at risk for or treated for CLTI should receive verbal and written instructions for self‑surveillance of recurrence. American College of Radiology (Class I, Level B). 24

13. Common Pitfalls to Avoid

• Do not proceed directly to revascularization without first completing a 3‑month trial of optimal medical therapy and supervised exercise in patients with intermittent claudication. ESC (Class III, Level A). 19
• Do not add warfarin to antiplatelet therapy without a clear indication, as it increases bleeding risk without cardiovascular benefit. AHA (Class III, Level A). 20
• Do not prescribe cilostazol to patients with heart failure because it is contraindicated. AHA (Class III, Level A). 20
• Do not delay referral to a vascular team in patients with CLTI; early recognition and treatment are critical for limb salvage. ESC (Class I, Level A). 19

Evidence‑Based Management of Peripheral Arterial Disease

Antiplatelet Therapy

• Clopidogrel 75 mg once daily is the preferred antiplatelet agent for all symptomatic PAD patients to lower myocardial infarction, stroke, and vascular death (Class I, Level A, ACC) 26.
• Aspirin 75–325 mg daily may be used only when clopidogrel is contraindicated or not tolerated (Class I, Level A, ACC) [26][27].

Blood‑Pressure Management

• Target BP < 140/90 mmHg in patients without diabetes and < 130/80 mmHg in those with diabetes or chronic kidney disease (Class I, Level A, ACC) [26][27].
• ACE inhibitors or ARBs are first‑line agents because they reduce cardiovascular events and may improve walking distance (Class I, Level A, ACC) [26][27].
• Beta‑blockers are safe and effective in PAD and do not worsen claudication (Class I, Level A, ACC) [26][27].

Smoking Cessation

• Screen every visit for tobacco use and provide counseling with a structured quit plan (Class I, Level A, ACC) 26.
• Offer pharmacologic aids (varenicline, bupropion, nicotine‑replacement therapy) unless contraindicated (Class I, Level A, ACC) 26.

Diabetes Management

• Aim for HbA1c < 7 % to reduce microvascular complications and potentially improve cardiovascular outcomes (Class I, Level A, ACC) [26][27].
• Implement daily foot‑care measures (appropriate footwear, podiatric review, daily inspection, skin hygiene, prompt treatment of lesions) (Class I, Level A, ACC) [26][27].

Pharmacologic Therapy for Claudication

• Cilostazol 100 mg twice daily should be prescribed to all patients with lifestyle‑limiting claudication to improve symptoms and walking distance (Class I, Level A, ACC) 26.
• Pentoxifylline 400 mg three times daily may be considered as a second‑line option when cilostazol is contraindicated, although its benefit is modest (Class IIb, Level C, ACC) 26.

Indications for Revascularization (after 3 months of optimal medical therapy & supervised exercise)

• Revascularization is appropriate only after completion of supervised exercise and pharmacotherapy with inadequate symptomatic response (Class I, Level B, ACC) 28.
• Patients must have significant disability affecting work or daily activities (Class I, Level B, ACC) 28.
• Ongoing comprehensive risk‑factor modification and antiplatelet therapy must be in place (Class I, Level B, ACC) 28.
• Lesion anatomy should present low procedural risk with a high likelihood of immediate and long‑term technical success (Class I, Level B, ACC) 28.

Critical Limb‑Threatening Ischemia (CLTI) – Emergency Management

• Early recognition of CLTI and immediate referral to a vascular team are essential for limb salvage (Class I, Level A, ACC) 28.
• Rapid assessment of amputation‑risk factors (diabetes, neuropathy, chronic renal failure, infection) should be performed (Class I, Level A, ACC) 28.
• Prompt initiation of systemic antibiotics is required in CLTI patients with ulceration or infection (Class I, Level A, ACC) 28.
• Referral to specialized wound‑care services should be arranged without delay (Class I, Level A, ACC) 28.
• Patients at risk for CLTI (ABI < 0.4 with diabetes or any diabetic with PAD) need regular foot inspection (Class I, Level A, ACC) 28.
• Patients with a prior episode of CLI should be evaluated at least twice yearly by a vascular specialist (Class I, Level A, ACC) 28.
• Any diabetic or high‑risk patient who develops acute limb symptoms must be assessed immediately as a vascular emergency (Class I, Level A, ACC) 28.

Follow‑up and Surveillance

• Post‑CLI patients require at least bi‑annual evaluation by a vascular specialist (Class I, Level A, ACC) 28.
• All PAD patients should receive verbal and written instructions for self‑surveillance of recurrence (Class I, Level A, ACC) 28.

Safety Considerations (Pitfalls to Avoid)

• Do not withhold beta‑blockers in PAD patients; they are safe and effective (Class I, Level A, ACC) [26][27].

Guideline Recommendations for Peripheral Vascular Disease (PAD) Management

Diagnosis and Initial Assessment

• The American College of Cardiology (ACC) recommends that all patients with suspected PAD undergo ankle‑brachial index (ABI) measurement as the first step, followed by comprehensive medical therapy (antiplatelet, high‑intensity statin, blood‑pressure control, smoking cessation, and ≥3 months of supervised exercise) before any revascularization is considered. 29
• Resting ABI should be measured in both legs to confirm PAD in patients with exertional leg symptoms, non‑healing wounds, age ≥ 65 years, or age ≥ 50 years with a smoking or diabetes history; an ABI ≤ 0.90 confirms PAD, whereas an ABI > 1.40 indicates non‑compressible vessels and warrants toe‑brachial index measurement. 29
• A comprehensive vascular assessment—including detailed symptom review, lower‑extremity pulse examination with direct foot inspection, and bilateral arm blood‑pressure measurement for subclavian stenosis—should be performed in all suspected PAD patients. 29
• Baseline laboratory testing (complete blood count, glucose, renal function) and a resting electrocardiogram are part of the initial work‑up. 30
• Duplex ultrasound is the preferred non‑invasive imaging modality to define the anatomic location and severity of arterial stenosis when revascularization is being contemplated. 29

Antiplatelet Therapy

• Clopidogrel 75 mg once daily is the preferred antiplatelet agent for symptomatic PAD patients to reduce myocardial infarction, stroke, and vascular death. 29
• Aspirin 75–325 mg daily is an acceptable alternative when clopidogrel cannot be used. 29

Supervised Exercise Training (SET)

• SET is the initial treatment for intermittent claudication and carries a Class I, Level A recommendation; it should be attempted for at least 12 weeks before any revascularization. 29

Pharmacologic Therapy for Claudication

• Cilostazol 100 mg twice daily improves walking distance and symptoms in patients with lifestyle‑limiting claudication; it is contraindicated in patients with heart failure. 29

Indications and Criteria for Revascularization

• Revascularization should be considered only after a ≥3‑month trial of optimal medical therapy and supervised exercise in patients with persistent lifestyle‑limiting symptoms and impaired quality of life. 29
• Before proceeding, all of the following criteria must be met:
  (All criteria supported by ACC evidence.) 29

Critical Limb‑Threatening Ischemia (CLTI)

• Early recognition of CLTI and immediate referral to a vascular team are essential for limb salvage. 30
• CLTI is defined by ischemic rest pain, ulceration, or gangrene; without treatment, major amputation occurs in most patients within 6 months. 30
• Patients with CLTI require expedited evaluation of amputation‑risk factors (diabetes, neuropathy, chronic renal failure, infection). 30
• Immediate systemic antibiotics should be administered for ulceration or infection associated with CLTI. 30
• Referral to specialized wound‑care providers is recommended for CLTI‑related ulcers. 30
• Patients at risk for CLTI (ABI < 0.4 with diabetes or any diabetic with known PAD) should undergo regular foot inspection. 30
• An absolute ankle systolic pressure ≤ 50 mmHg (or toe pressure ≤ 30 mmHg) often predicts that amputation may be required if revascularization is not feasible. 30
• Patients with diabetes, neuropathy, chronic renal failure, or infection who develop acute limb symptoms constitute a vascular emergency and must be assessed immediately by a vascular specialist. 30

Acute Limb Ischemia (ALI)

• In patients with ALI and a salvageable extremity, emergent evaluation of the occlusion level and prompt endovascular or surgical revascularization are required. 29
• If the limb is non‑viable, no vascular anatomy evaluation or revascularization attempts should be performed. 29

Follow‑up and Surveillance

• Patients with prior CLTI or successful CLTI treatment should be evaluated at least twice yearly by a vascular specialist because of the high risk of recurrence. 30
• Long‑term patency of infra‑inguinal bypass grafts should be monitored with a surveillance program that includes clinical history, resting ABI, physical examination, and duplex ultrasound at 3, 6, 12 months and then annually. 29
• All patients at risk for or treated for CLTI should receive verbal and written instructions for self‑surveillance of recurrence. 30